

ORIGINAL PAPER

Available from: <http://www.jgld.ro/wp/archive/y2016/n2/a5>DOI: <http://dx.doi.org/10.15403/jgld.2014.1121.252.2w3>

Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line *H. pylori* Eradication

Vincenzo De Francesco¹, Lorenzo Ridola², Cesare Hassan³, Annamaria Bellesia¹, Domenico Alvaro², Dino Vaira⁴, Angelo Zullo³

1) Gastroenterology Unit, Riuniti Hospital, Foggia;
2) Gastroenterology Unit, Sapienza University of Rome, Polo Pontino, Latina;
3) Gastroenterology and Digestive Endoscopy, Nuovo Regina Margherita Hospital, Rome;
4) Department of Medical and Surgical Sciences, University of Bologna, Bologna Italy

ABSTRACT

Background & Aims: The updated Italian guidelines advise a standard 14-day triple therapy for first-line *H. pylori* eradication. This prospective study evaluated the cure rate following a 14-day triple therapy with either a standard or double-dose proton pump inhibitor (PPI).

Methods. A total of 145 consecutive patients with *H. pylori* infection were randomized to receive a 14-day, first-line triple therapy with clarithromycin 500 mg, amoxicillin 1 g and esomeprazole at either 20 mg (standard therapy) or 40 mg (double-dose therapy), each given twice daily.

Results. At intention-to-treat analysis, *H. pylori* infection was cured in 73.9% (95% CI: 63.9–84) and 81.9% (95% CI: 73–90.8) following standard and double-dose therapy, respectively, and in 78.2% (95% CI: 68.5–87.9) and 85.5% (95% CI: 77.2–93.8) at per-protocol analysis. No statistically significant difference occurred. Overall, 16.4% and 19.4% patients in the standard and double-dose therapy regimen complained of side effects.

Conclusion. The success rate of both standard and double-dose 14-day triple therapies for first-line *H. pylori* treatment was unsatisfactory. A prolonged 14-day levofloxacin-based triple therapy for second-line *H. pylori* eradication seems to be promising.

Key words: *Helicobacter pylori* – triple therapy – levofloxacin – rescue therapy.

Abbreviations: ITT: Intention To Treat; NUD: non ulcer dyspepsia; PP: Per Protocol; PPI: proton pump inhibitors; PUD: peptic ulcer disease; UBT: urea breath test.

Address for correspondence:
Vincenzo De Francesco, M.D.
Section of Gastroenterology
Department of Medical Sciences
University of Foggia,
Ospedali Riuniti
Viale L. Pinto 71100,
Foggia, Italy
Email: vdefrancesco@ospedaliriunitifoggia.it

INTRODUCTION

In the last decade, the *H. pylori* eradication rate following standard 7-day triple therapies has fallen to unacceptably low cure rates worldwide [1]. This has been largely attributed to the increased prevalence of primary resistance towards clarithromycin and metronidazole, widely used for *H. pylori* treatment [2, 3]. Therefore, current European guidelines suggest the use of a prolonged 10-14 days first-line triple therapy in those areas where primary clarithromycin resistance is >15-20% [4]. In addition, the use of high-dose (twice daily) proton pump inhibitor (PPI) should be considered to further increase

the efficacy of triple therapy [4]. The updated Italian guidelines advise a standard 14-day triple therapy for first-line *H. pylori* eradication [5]. However, following such a therapy, a cure rate less than the auspicated 90% was observed in some trials [6-8]. To our knowledge, no study has evaluated the efficacy of a 14-day triple therapy including double-dose PPI in Italy. We therefore designed a prospective study to evaluate the cure rate following a 14-day triple therapy with either standard or double-dose PPI in a central-southern Italian region with a high prevalence of clarithromycin resistance. As a secondary aim, the efficacy of a 14-day, levofloxacin-based triple therapy for second-line treatment in the eradication failure patients was tested.

MATERIAL AND METHODS

Patients

Consecutive patients complaining of dyspeptic symptoms referred for upper endoscopy in the participating three centres (Foggia, Rome, Latina) were considered for recruitment into the study. Exclusion criteria were: 1) age <18 years; 2) previous eradication therapy failures; 3) consumption of PPI and/or

Received: 03.01.2016

Accepted: 02.03.2016

antibiotics in the previous two months; 4) previous gastric surgery; 5) liver cirrhosis or kidney failure, alcohol abuse, pregnancy, and known allergy to antibiotics. For all patients an informed consent was obtained.

Endoscopy and *H. pylori* detection

All patients underwent upper endoscopy, and five gastric biopsies were taken according to the updated Sydney System [9]. *H. pylori* infection was considered present when bacteria together with an active chronic gastritis were detected at histology, on Eosin & Hematoxylin staining and modified Giemsa staining in doubtful cases, as performed in clinical practice. The presence of a peptic ulcer was defined as mucosal ulceration >5 mm in diameter. For the purpose of the study, patients with duodenal or gastric ulcer were considered as having peptic ulcer disease (PUD), while those without macroscopic mucosal abnormalities were considered as non-ulcer dyspeptic patients (NUD). Bacterial eradication was checked 6–8 weeks following therapy by using a standard ¹³C-urea breath test (UBT) with a cut-off value of 3.5%, according to the manufacturer's recommendations. The UBT control was performed in laboratories not involved in the study.

Therapy regimens

This was a prospective, open-label, randomized study. Patients were randomized by a computer-generated list to receive a 14-day triple therapy with clarithromycin 500 mg, amoxicillin 1 g and esomeprazole at either 20 mg or 40 mg dose. All drugs were given twice daily, with PPI given half-hour before breakfast and dinner, and antibiotics following these meals. Patients were thoroughly instructed and motivated to the therapy. At the end of the treatment, both side effects and therapeutic compliance were assessed by personal interview. A pill intake >90% was considered as good compliance. When first-line therapy failed, a second-line therapy regimen with esomeprazole 20 mg, amoxicillin 1 g, and levofloxacin 250 mg, all twice daily, was administered for 14 days. The cost of therapies was calculated based on number of tablets required for the entire treatment by including only brand drugs.

Statistical analysis

Comparisons between patient groups were performed by using the T-test for unpaired data and the Chi-square test, as appropriate. The eradication rates with their 95% confidence intervals (CIs) were calculated at both 'intention-to-treat' (ITT) and at 'per protocol' (PP) analyses. At ITT all the enrolled patients were included, whilst at PP only compliant patients who underwent UBT control were considered. Before pooling data, the observed eradication rates were compared to exclude a statistically significant difference among centres. Differences were considered significant at a 5% probability level. SPSS was used for statistical analysis.

RESULTS

One-hundred and forty-five patients were enrolled from January to November 2015, including 73 and 72 patients in the standard and double-dose therapy regimen, all included at ITT analysis. A total of 7 patients were considered drop-outs due

to either early therapy interruption for side-effects (3 cases) or because they had failed to attend the UBT control (4 cases). Therefore, there were 69 and 69 patients at PP analysis. No statistically significant differences were present between the two groups at entry, except of a higher prevalence of females in the standard regimen (Table I). Overall, 12 (16.4%) and 14 (19.4%) patients in the standard and double-dose therapy regimen complained of side-effects, including abdominal pain/nausea (12), mild diarrhoea (11), metallic taste (3), itching (2), and urticaria (1). In 3 cases, the therapy was earlier stopped (at 3, 10 and 12 days).

Table I. Demographic and clinical characteristics of the enrolled patients.

	Standard-dose PPI	High-dose PPI	P Value
Number of patients	73	72	-
Age (mean±SD) years	51.2 ± 14.2	47.9 ± 15.8	0.3
Sex male/female	21/52	32/40	0.0499
Smoking habit (Yes/No)	16/57	25/47	0.12
Disease: NUD/PUD	64/9	68/4	0.25

PPI: proton pump inhibitor; NUD: non-ulcer dyspepsia; PUD: peptic ulcer disease.

As shown in Table II, the cure rate following the double-dose PPI regimen was higher than the standard-dose at both ITT (+8%) and PP (+7.3%), although the differences were not statistically significant. Moreover, only for the double-dose regimen the high 95% CI limit was superior to 90%, at both ITT and PP analysis. By considering all the 145 patients included in the PP analysis, the eradication rate tended to be lower in PUD than in NUD patients (69.2% vs 83.2%), whilst similar cure rates occurred in males and females (82.4% vs 81.4%), as well as in smokers and no smokers (81.3% vs 82.1%). In Italy, the cost of treatment was 44.82 and 54.71 Euros for standard and double-dose PPI regimen, respectively.

Table II. *H. pylori* eradication rates.

Eradication rate	Standard-dose PPI	Double-dose PPI	P value
ITT analysis; N (%; 95%CI)	54/73 (73.9; 63.9–84)	59/72 (81.9; 73–90.8)	0.25
PP analysis; N (%; 95%CI)	54/69 (78.2; 8.5–87.9)	59/69 (85.5; 7.2–93.8)	0.27

A total of 16 out of 25 eradication failure patients agreed to perform the second-line levofloxacin-based triple therapy. The infection was cured in 14 (87.5%; 95%CI 71.3–100). Compliance was good in all these patients, and side-effects occurred in 3 (18.7%) cases, including mild diarrhoea (2 patients) and itching (1 patient).

DISCUSSION

Standard triple therapies remain the mostly used first-line treatment for *H. pylori* eradication in clinical practice. Unfortunately, the success rate following either 7–10 days triple

therapies has declined to unacceptably low values in Italy [10], and several factors have been advocated as potential causes of therapy failure [11]. Therefore, the current European and Italian guidelines have suggested prolonging to 14 days the standard triple therapy duration in those areas with a high prevalence of primary clarithromycin resistance [4, 5]. Indeed, it has been found that a longer triple therapy significantly increased the cure rate as compared to the 7-10 days regimen [12-16]. The use of increased PPI doses is another suggestion to improve the cure rate of triple therapies [4]. In Southern and Central Italy, where this study was performed, the prevalence rate of primary clarithromycin resistance has been found to be higher than 20% [17, 18]. Based on these observations, we performed this study to test the efficacy of 14-day triple therapy with either standard or double PPI doses for first-line *H. pylori* eradication. Our data found that both these triple therapies achieved unsatisfactory eradication rates, with values <80% at ITT analysis. In detail, the cure rate following the standard 14-day triple therapy regimen was consistent to 70-81.7% eradication rates achieved in other Italian studies [5-8], as well as to 74.8-82.2% observed in other countries, such as Germany, Korea, and Latin America [10, 19]. Following the 14-day triple therapy with double-dose PPI we observed a trend towards increased (7-8%) eradication rates when compared to the standard regimen. However, even following this therapy the cure rate was 81.9-85.5%. To our knowledge, the efficacy of this therapy regimen has been tested only in another study recently performed in Spain, where the eradication rates were 81.3-82.3% [20]. Although modest, such a therapeutic gain in the presence of high clarithromycin resistance is probably clinically advantageous when considering that the cost of therapy, in Italy, is increased by only 10 Euros.

According to current guidelines [4, 5] we administered a levofloxacin-based triple regimen as a second-line therapy. Since we previously found that the cure rate following a standard 10-day regimen is decreasing, with an eradication rate ranging from 55.6% to 72.6% [21-23], a 14-day therapy was chosen. Worth noting is that such a therapy achieved an encouragingly high (87.5%) eradication rate. A similarly prolonged levofloxacin-based triple, with double-dose PPI, achieved 84.8-93.6% success rates in Taiwan [24, 25]. However, when a regimen with increased doses was administered for only 8 days, the eradication rate was only 60-64% [26]. These observations suggest that the therapy duration of levofloxacin-based second-line therapy should be prolonged to 14 days rather than increasing the drugs dosage. Further studies are required to confirm these results. On the other hand, the three-in-one pill, bismuth-based therapy could be useful as a rescue therapy, and its commercialization is awaited in our country.

CONCLUSION

The standard 14-day triple therapy seems to be unsuccessful for first-line *H. pylori* treatment in those areas with a high primary clarithromycin resistance, such as in Italy. Whether a double-dose PPI regimen is able to significantly increase the success rate needs to be proven in further studies. The efficacy of prolonged 14-day levofloxacin-based triple therapy for second-line *H. pylori* eradication seems to be promising.

Conflicts of interest: None to declare.

Authors' contribution: V.de F. and A.Z. designed the study, enrolled patients, and wrote the manuscript; C.H. analyzed the data; A.B. and L.R. collected literature data; D.A. and D.V. performed internal critical revision. All authors approved the final version of the manuscript.

REFERENCES

- Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. *Gut* 2010; 59: 1143-1153. doi: [10.1136/gut.2009.192757](https://doi.org/10.1136/gut.2009.192757)
- De Francesco V, Giorgio F, Hassan C, et al. Worldwide *H. pylori* antibiotic resistance: a systematic review. *J Gastrointest Liver Dis* 2010; 19: 409-414.
- Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. *Gut* 2013; 62: 34-42. doi: [10.1136/gutjnl-2012-302254](https://doi.org/10.1136/gutjnl-2012-302254)
- Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. *Gut* 2012; 61: 646-664. doi: [10.1136/gutjnl-2012-302084](https://doi.org/10.1136/gutjnl-2012-302084)
- Zagari RM, Romano M, Ojetti V, et al. Guidelines for the management of Helicobacter pylori infection in Italy. The III Working Group Consensus Report 2015. *Dig Liver Dis* 2015; 47: 903-912. doi: [10.1016/j.dld.2015.06.010](https://doi.org/10.1016/j.dld.2015.06.010)
- Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of one and two weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER study. *Gut* 2007; 56: 475-479. doi: [10.1136/gut.2006.102269](https://doi.org/10.1136/gut.2006.102269)
- Paoluzi P, Iacopini F, Crispino P, et al. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. *Helicobacter* 2006; 11: 562-568. doi: [10.1111/j.1523-5378.2006.00459.x](https://doi.org/10.1111/j.1523-5378.2006.00459.x)
- Zullo A, Severi C, Vannella L, Hassan C, Sbrozzi-Vanni A, Annibale B. Role of gastritis pattern on Helicobacter pylori eradication. *Intern Emerg Med* 2012; 7: 517-522. doi: [10.1007/s11739-011-0730-4](https://doi.org/10.1007/s11739-011-0730-4)
- Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* 1996; 20: 1161-1181.
- Zullo A, Hassan C, Ridola L, De Francesco V, Vaira D. Standard triple and sequential therapies for Helicobacter pylori eradication: an update. *Eur J Intern Med* 2013; 24: 16-19. doi: [10.1016/j.ejim.2012.07.006](https://doi.org/10.1016/j.ejim.2012.07.006)
- Zullo A, De Francesco V, Hassan C. Predicting Helicobacter pylori eradication: How to teach an old dog new tricks! *J Clin Gastroenterol* 2012; 46: 259-261. doi: [10.1097/MCG.0b013e318247177e](https://doi.org/10.1097/MCG.0b013e318247177e)
- Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication. *Ann Intern Med* 2007; 147: 553-562. doi: [10.7326/0003-4819-147-8-200710160-00008](https://doi.org/10.7326/0003-4819-147-8-200710160-00008)
- Gatta L, Vakili N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. *Am J Gastroenterol* 2009; 104: 3069-3079. doi: [10.1038/ajg.2009.555](https://doi.org/10.1038/ajg.2009.555)
- Gatta L, Vakili N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. *BMJ* 2013; 347: f4587. doi: [10.1136/bmj.f4587](https://doi.org/10.1136/bmj.f4587)

15. Li BZ, Threapleton DE, Wang JY, et al. Comparative effectiveness and tolerance of treatments for *Helicobacter pylori*: systematic review and network meta-analysis. *BMJ* 2015; 351: h4052. doi: [10.1136/bmj.h4052](https://doi.org/10.1136/bmj.h4052)
16. Liou JM, Chen CC, Chang CY, et al; Taiwan Gastrointestinal Disease and *Helicobacter* Consortium. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of *Helicobacter pylori* in the community and hospital populations: a randomised trial. *Gut* 2015 Sep 3. doi: [10.1136/gutjnl-2015-310142](https://doi.org/10.1136/gutjnl-2015-310142)
17. De Francesco V, Margiotta M, Zullo A, et al. Primary clarithromycin resistance in Italy assessed on *Helicobacter pylori* DNA sequences by TaqMan real-time polymerase chain reaction. *Aliment Pharmacol Ther* 2006; 23: 429-435. doi: [10.1111/j.1365-2036.2006.02769.x](https://doi.org/10.1111/j.1365-2036.2006.02769.x)
18. De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in *Helicobacter pylori* strains over a 15 year period in Italy. *J Antimicrob Chemother* 2007; 59: 783-785. doi: [10.1093/jac/dkm005](https://doi.org/10.1093/jac/dkm005)
19. Dammann HG, Folsch UR, Hahn EG, et al. Eradication of *H. pylori* with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. *Helicobacter* 2000; 5: 41-51. doi: [10.1046/j.1523-5378.2000.00006.x](https://doi.org/10.1046/j.1523-5378.2000.00006.x)
20. Molina-Infante J, Lucendo AJ, Angueira T, et al. Optimised empiric triple and concomitant therapy for *Helicobacter pylori* eradication in clinical practice: the OPTRICON study. *Aliment Pharmacol Ther* 2015; 41: 581-589. doi: [10.1111/apt.13069](https://doi.org/10.1111/apt.13069)
21. Zullo A, De Francesco V, Manes G, Scaccianoce G, Cristofari F, Hassan C. Second-line and rescue therapies for *Helicobacter pylori* eradication in clinical practice. *J Gastrointest Liver Dis* 2010; 19: 131-134.
22. De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for *Helicobacter pylori* eradication: a prospective randomized study. *J Med Microbiol* 2014; 63: 748-752. doi: [10.1099/jmm.0.072322-0](https://doi.org/10.1099/jmm.0.072322-0)
23. Zullo A, Scaccianoce G, De Francesco V, et al. Concomitant, sequential, and hybrid therapy for *H. pylori*. A pilot study. *Clin Res Hepatol Gastroenterol* 2013; 37: 647-650. doi: [10.1016/j.clinre.2013.04.003](https://doi.org/10.1016/j.clinre.2013.04.003)
24. Tai WC, Lee CH, Chiou SS, et al. The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line *Helicobacter pylori* eradication. *PLoS ONE* 2014; 9: e105822. doi: [10.1371/journal.pone.0105822](https://doi.org/10.1371/journal.pone.0105822)
25. Chuah SK, Tai WC, Hsu PI, et al. The efficacy of second-line anti-*Helicobacter pylori* therapy using an extended 14-days levofloxacin/amoxicillin/proton pump inhibitors - a pilot study. *Helicobacter* 2012; 17: 374-381. doi: [10.1111/j.1523-5378.2012.00960.x](https://doi.org/10.1111/j.1523-5378.2012.00960.x)
26. Zullo A, Ridola L, Efrati C, et al. First- and second-line *Helicobacter pylori* eradication with modified sequential therapy and modified levofloxacin-amoxicillin-based triple therapy. *Ann Gastroenterol* 2014; 27: 357-361.